Molecular Partners AG | Mutual Funds
Mutual Funds that own Molecular Partners AG
Pictet (CH) - Swiss Mid Small Cap
543,427
2.56%
0
0.81%
03/31/2018
UBAM - Swiss Equity
350,495
1.65%
-4,449
0.41%
12/31/2017
IST - Aktien Schweiz Ergaenzungswerte
255,353
1.2%
-425
0.57%
07/31/2018
Julius Baer (CH) Swiss Sustainable
232,421
1.1%
-3,572
1.62%
05/31/2018
Vontobel Swiss Small Companies
230,000
1.08%
-50,000
1.76%
05/31/2018
UBS (CH) Institutional Fund - Small & Mid Cap Equities Switzer
176,675
0.83%
-7,145
0.39%
12/29/2017
Julius Baer Multistock - JB EF Swiss Stock Fund
156,896
0.74%
1,629
1.67%
05/31/2018
UBS (Lux) Equity Fund - Biotech
155,908
0.74%
0
0.28%
01/31/2018
Vontobel Fund - Swiss Mid & Small Cap Equity
144,000
0.68%
50,000
0.88%
05/31/2018
Pictet (CH) Enhanced - Swiss Equities 130/30
125,540
0.59%
0
0.51%
03/31/2018
| Address |
Wagistrasse 14
Zurich Zurich 8952
Switzerland
|
|
Employees
|
- |
| Website |
http://www.molecularpartners.com |
| Updated |
07/08/2019 |
| Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun and Michael Tobias Stumpp on November 23, 2004 and is headquartered in Zurich, Switzerland. |
